Clearfield reports its Q2 2026 results today, and the most striking feature of the setup is a sharp build in short interest over the past month — even as the stock has quietly recovered.
Short interest has climbed 53% over the past month to reach 12.2% of the free float, a level that ranks in the 2nd percentile of the universe — meaning almost every stock in the market carries less short pressure than Clearfield right now. ORTEX's short score confirms the picture at 72, near its highest reading of the recent period. Yet the borrow market itself remains loose. Cost to borrow is just 0.62%, and borrow availability is ample — bears are not fighting each other for access to shares. That combination of elevated short interest and easy borrow suggests the shorts are patient and deliberate, not squeezed or panicked.
The stock has not buckled under that pressure. Clearfield closed at $30.28 on Wednesday, up 8.5% on the week and 14% over the past month — a rally that has run directly against the grain of the rising short position. Peer performance has been mixed: HLIT and CRNT added 16% and 13% respectively on the week, supporting a broader sector lift, while dropped 17% in a single session and shed 29% — a reminder of how badly this group can react to a disappointing print. Options positioning has leaned defensively in recent weeks, with the put/call ratio running well above 1.0 since late April. At 1.21 on Wednesday, it is well above its 20-day average of 0.95 — though still below the 52-week high of 1.64 hit on April 29, suggesting the worst of the hedging demand has eased slightly.
The bull and bear cases are well-defined. Bulls point to Clearfield's franchise in fiber management and delivery, its cash balance, and the long runway from rural broadband investment. The most compelling fundamental signal is the forward EPS estimate trajectory, which ranks in the 98th percentile for year-on-year improvement — and the company has beaten estimates at a 91st-percentile rate historically. Analyst consensus (as of late November 2025, the last material update cycle) remains firmly positive: multiple firms hold Buy or Outperform ratings with targets clustering in the $41–$45 range, implying roughly 44% upside to the current price. Bears focus on BEAD-program delays, government funding uncertainty, and execution risk. The prior earnings print in February produced a 4.5% one-day drop and a 6.3% five-day slide — a useful data point on how the market has previously treated cautious guidance from this company.
Chairman Ronald Roth bought 10,000 shares at $30.06 in December, a signal that the largest individual holder added at nearly today's price level. That context sits alongside the aggressive short build — two distinct camps, both active, both sized, heading into the same print tonight.
See the live data behind this article on ORTEX.
Open CLFD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
